{"analyses":[{"ciLowerLimit":".735","ciPctValue":"95","ciUpperLimit":".979","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Binomial proportion","paramValue":".9","statisticalMethod":"Binomial proportion","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}],"title":"Experienced Grade 3 or 4 toxicities"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Did not experience Grade 3 or 4 toxicities"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"To estimate proportion of patients experiencing CTC Grade 3 or 4 toxicity during Induction II (Cytarabine + Daunomycin + Etoposide (ADE) + GO), who had no response to first course of induction therapy","groups":[{"description":"Post-GO Treatment MRD","id":"OG000","title":"Overall"}],"paramType":"NUMBER","populationDescription":"30 patients received ADE + GO during induction II and were analyzed. Out of the 30 patients, 11 patients were treated on HDAC arm, and 19 patients were treated on LDAC arm.","reportingStatus":"POSTED","timeFrame":"Induction II","title":"Proportion of Patients Experienced Toxicity of Cytarabine + Daunomycin + Etoposide (ADE) + GO.","type":"SECONDARY","unitOfMeasure":"Participants"}